Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

23. Februar 2016 06:30 ET | Quelle: CytoDyn Inc.

CytoDyn Initiates Phase 3 Monotherapy Trial for HIV Patients

VANCOUVER, Wash., Feb. 23, 2016 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency...
28. Januar 2016 06:30 ET | Quelle: CytoDyn Inc.

CytoDyn Reports Full Virologic Suppression in Eleven HIV Patients on PRO 140 Monotherapy for Up to 17 Months

VANCOUVER, Wash., Jan. 28, 2016 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus...
22. Januar 2016 06:30 ET | Quelle: CytoDyn Inc.

CytoDyn Files Request for Breakthrough Therapy Designation With the FDA for Use of PRO 140 in HIV Therapy

VANCOUVER, Wash., Jan. 22, 2016 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV)...
20. Januar 2016 06:30 ET | Quelle: CytoDyn Inc.

CytoDyn Appoints Denis R. Burger, Ph.D., as Chief Science Officer

VANCOUVER, Wash., Jan. 20, 2016 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV)...
19. Januar 2016 06:30 ET | Quelle: CytoDyn Inc.

CytoDyn Announces HIV-Patients Approaching 17 Months of Complete Viral Suppression With PRO 140 Monotherapy

CytoDyn to file an additional Phase 3 Protocol for HIV MonotherapyInvestment Community Conference Call Scheduled for January 21, 2016VANCOUVER, Wash., Jan. 19, 2016 (GLOBE NEWSWIRE) -- CytoDyn...
22. Dezember 2015 08:30 ET | Quelle: CytoDyn Inc.

CytoDyn Files for Orphan Drug Designation for Use of PRO 140 in Graft Versus Host Disease

VANCOUVER, Wash., Dec. 22, 2015 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV)...
21. Dezember 2015 16:02 ET | Quelle: CytoDyn Inc.

FDA Clears CytoDyn for Relaxed Entry Criteria for Its Ongoing Phase 3 Trial in HIV-Infected Patients

VANCOUVER, Wash., Dec. 21, 2015 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus...
14. Dezember 2015 08:30 ET | Quelle: CytoDyn Inc.

CytoDyn Receives FDA Clearance for Its First Non-HIV Indication for PRO 140

VANCOUVER, Wash., Dec. 14, 2015 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV)...
21. August 2012 16:56 ET | Quelle: CytoDyn Inc.

CytoDyn Announces Management Update Conference Call on Thursday, August 23

LUTZ, Fla., Aug. 21, 2012 (GLOBE NEWSWIRE) -- CytoDyn Inc. (the "Company") (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune...
13. April 2012 15:11 ET | Quelle: CytoDyn Inc.

CytoDyn Engages the Trout Group for Investor Relations Services

LUTZ, Fla., April 13, 2012 (GLOBE NEWSWIRE) -- CytoDyn Inc. (the "Company") (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune...